Dr. Dorothy Mbori-Ngacha from UNICEF presented a sobering picture of the potential to eliminate 90 percent of HIV infections among children by 2015—the goal established by UNAIDS and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program in June of 2011. She outlined the four pillars of the achieving that goal at the 19th […]
The following is a guest blog post by HIV Medicine Association Executive Director, Andrea Weddle, who is live blogging from the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) […]
Results from two National Institutes of Health (NIH)-funded studies presented Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections underscore the importance of identifying and treating HIV-infected infants in the first year of life to protect their immune systems and to enable normal neurological development. Jintanat Ananworanich, MD, PhD, presented findings from the PREDICT […]
On Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections, Dr. Landon Myer presented data from a study of 29,653 HIV infected women initiating antiretroviral therapy (ART) in the public sector in South Africa from 2002 to 2009. The aim of the study was to compare loss to follow-up rates of pregnant women and […]
Investigators hinted at a way to improve upon the HIV prevention results achieved in the CAPRISA 004 one percent tenofovir vaginal microbicide study, which found a 39 percent protective benefit for women using the pre- and post- coital gel. Lead CAPRISA investigators Drs. Salim and Quarraisha Abdool Karim broached the subject during a thoughtful plenary […]
Investigators presented more data dissecting the link between hormonal contraceptives and HIV transmission and disease progression Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. Oral and Injectable Contraception use and risk of HIV acquisition among women, MIRA study Dr. Sandra McCoy reported on a secondary data analysis of hormonal contraception and […]
The Microbicides Trial Network released promising results from its “MTN-007” Phase I safety and acceptability study, funded by the National Institutes of Health, looking at a new formulation of one percent tenofovir gel for rectal use Tuesday. The results were presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Earlier formulations […]
Investigators gave more details about the positive results of the Partners PrEP Study Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. The study of 4,700 HIV discordant couples (where one partner is HIV-infected and the other is not) looked at the potential of two different antiretrovirals for pre-exposure prophylaxis (PrEP) for […]
The World Health Organization released updated guidance Friday with updated global policy for prevention, diagnosis and treatment of both HIV and tuberculosis (TB). The WHO released initial guidance in 2004 – and in the past six years approximately 910,000 lives have been saved worldwide thanks to improved collaboration between HIV and TB services, protecting people […]
HIV
By Richard Ngethe, MBA, Data.FI As a data clerk in Kenya in 2005, my challenge was to work at rural hospitals digitizing client-level longitudinal data for […]
Tuberculosis
The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed […]
Research & Development
By Mitchell Warren, executive director, AVAC In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN […]
Policy
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]